Weight loss jabs like Ozempic and Wegovy cut risk of bowel cancer by half - and boost breast cancer survival by a third, study suggests By Kate Pickles Health Editor For The Daily Mail In Chicago Published: 18:35, 4 June 2024 | Updated: 18:48, 4 June 2024 e-mail 12 View comments Weight loss jabs could start a 'revolution' in cancer care — slashing cases and deaths, world-leading experts suggest. The likes of Ozempic and Wegovy can cut the risk of obesity-related cancers by a fifth and bowel cancer by half, according to breakthrough research. Trial results presented at the world's largest cancer conference found breast cancer patients who took the class of drugs were a third less likely to be dead five years later.
Doctors say it will be the 'icing on the cake' if the medicines, which have been shown to cut heart attack and strokes, had a comparable effect on cancer. Significantly, they believe there are 'multiple ways' they help lessen the risks of cancer, in addition to the weight loss they are famed for. Shown above is a package of Wegovy.
Taken as weekly injections, it has been in shortage across the US amid its potential to help with weight loss Revolutionary weight-loss injections such as Wegovy and Ozempic could reduce the risk of some of the most common and deadly cancers (Stock image) Wegovy and Ozempic work by triggering the body to produce a hormone called GLP-1 that is released naturally from the intestines after meals The GLP-1 agonist drugs, a new class of medi.